Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 28.84 USD -2.67%
Market Cap: 4.1B USD
Have any thoughts about
Denali Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one DNLI stock under the Base Case scenario is 16.9 USD. Compared to the current market price of 28.84 USD, Denali Therapeutics Inc is Overvalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DNLI Relative Value
Base Case
16.9 USD
Overvaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
44
Median 3Y
31
Median 5Y
31
Industry
8.1
Forward
236.6
vs History
vs Industry
Median 3Y
-12.8
Median 5Y
-11.9
Industry
23
Forward
-10.7
vs History
vs Industry
Median 3Y
-12.5
Median 5Y
-12.6
Industry
23.4
vs History
vs Industry
Median 3Y
-12
Median 5Y
-11.9
Industry
27.3
vs History
63
vs Industry
41
Median 3Y
3.4
Median 5Y
4.2
Industry
2.6
vs History
vs Industry
46
Median 3Y
21.2
Median 5Y
22.1
Industry
8.1
Forward
189.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8.2
Industry
4.3
Forward
-7.2
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-7.9
Industry
3.8
Forward
-6.9
vs History
vs Industry
Median 3Y
-8.5
Median 5Y
-9
Industry
6
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-8.4
Industry
3.8
vs History
80
vs Industry
38
Median 3Y
11.9
Median 5Y
13.7
Industry
4.8

Multiples Across Competitors

DNLI Competitors Multiples
Denali Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Denali Therapeutics Inc
NASDAQ:DNLI
4.1B USD 0 -9.7 -6.7 -6.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.4 17.5 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 11.9 -263.9 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 4.1 910.1 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 6.3 18.8 17.3 19.2
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
US
Denali Therapeutics Inc
NASDAQ:DNLI
Average P/E: 211.8
Negative Multiple: -9.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Denali Therapeutics Inc
NASDAQ:DNLI
Average EV/EBITDA: 17.9
Negative Multiple: -6.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
US
Denali Therapeutics Inc
NASDAQ:DNLI
Average EV/EBIT: 23.2
Negative Multiple: -6.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top